Arsycap

What Arsycap does

Arsylab (legal entity ARSYLAB SASU) is a French medical-device company founded in June 2016 and headquartered in Thorigné-Fouillard, operating as a subsidiary of AEG Medical Group. The company develops, manufactures and distributes intra-articular hyaluronic acid (HA) injection products for osteoarthritis and adjacent musculoskeletal indications. Its core franchise, ARSYVISC, comprises multiple viscosupplementation SKUs (1.6%, 2.2%, Forte mono-injection, Forte+), extended by the premium cross-linked HYAJOINT Plus, the INNORYOS "visco-booster" combining HA with niacinamide, and ARSYPACK sterile procedure kits that bundle devices for clinical use. The underlying technology platform is non-animal-origin, biofermentation-derived, high-molecular-weight linear HA, produced for both standalone and premium positioning.

Arsylab runs a multi-channel go-to-market in France: direct-to-consumer via its arsylab.com e-commerce site, B2B2C through pharmacy distribution, direct sales to hospitals and clinics via a regional sales-representative team covering all metropolitan regions, and DOM-TOM (French overseas territory) coverage through third-party distributors GB PHARMA and Olivier Surveillant. Pricing is not publicly disclosed and the products are not reimbursed by the French national health insurance system following the December 2017 de-reimbursement decision, making the business a cash-pay model with typical repeat-purchase cycles of 6–12 months. Distribution is anchored on a national sales force that reached full metropolitan coverage in 2024.

Leadership is founder-led, with co-founder Erwann Corbel serving as Président Directeur Général alongside co-founder Didier Caradec, supported by a Commercial Director, a Head of Strategy & Development, a quality/regulatory function and a full back office (accounting, logistics, HR). The company has disclosed no external funding rounds and is implicitly capitalized through its AEG Medical Group parent. A new corporate headquarters was begun in 2023 to accommodate ongoing headcount and logistics growth.

Name

Arsycap

Legal name

ARSYLAB SASU

Website

https://arsylab.com

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

1–10 employees

Short description

Arsylab is a French medical-device company that develops and distributes biofermentation-derived hyaluronic acid intra-articular injections (ARSYVISC, HYAJOINT Plus, INNORYOS) for osteoarthritis patients via D2C, pharmacy, hospital and DOM-TOM channels across France.

Ownership category

akta.pro rank

Product category

Viscosupplementation Medical Devices

NAICS

Surgical Appliance and Supplies Manufacturing (339113)

SIC

Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)

akta.pro primary industry

Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM) (HLAHAEAG)

Keywords

• Viscosupplementation products
• Intra-articular hyaluronic acid
• Osteoarthritis medical devices
• Joint pain treatment
• Sterile injection kits

Headquarters

HQ city

Rennes

HQ country

France

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Personnel, Supply Chain, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Medical Device Sales (Viscosupplementation Products): Sale of proprietary hyaluronic acid-based intra-articular gels and sterile injection kits for osteoarthritis treatment. Products are prescription medical devices sold to healthcare professionals (pharmacists, hospitals) and directly to patients via B2C e-commerce. Revenue is one-time per transaction with repeat purchase dynamics driven by treatment cycles (effects lasting 6–12 months). ANSM-declared medical devices; not reimbursed by national health insurance since December 2017.

Pricing tiers

Go-to-market motion1 record

Distribution channels4 records

Marketing channels4 records

Core offering

Arsycap develops, manufactures, and commercializes hyaluronic acid-based intra-articular viscosupplementation medical devices for osteoarthritis treatment. The product range includes ARSYVISC gels (multiple formulations), HYAJOINT Plus cross-linked hyaluronic acid, INNORYOS (first HA+niacinamide visco-booster), and ARSYPACK sterile injection kits. Products are sold directly to patients via e-commerce and through pharmacies, hospitals, and physicians across France.

Product overview

Arsylab is a specialized pharmaceutical company focused on viscosupplementation treatments for osteoarthritis. Their product portfolio centers on hyaluronic acid-based medical devices: ARSYVISC (intra-articular gels for joint pain relief), HYAJOINT Plus (premium cross-linked hyaluronic acid solution), INNORYOS (hyaluronic acid + niacinamide visco-booster), and ARSYPACK (sterile injection procedure kits). All products are manufactured in Europe and designed for various joints including knee, hip, ankle, shoulder, and fingers.

Differentiator

Problem solved

Functional benefit

Brands

• ARSYVISC: Intra-articular gels for viscosupplementation for knee osteoarthritis treatment.
• HYAJOINT Plus
• ARSYPACK
• INNORYOS

Products and services

• ARSYVISC Range of intra-articular hyaluronic acid gels for viscosupplementation treatment of osteoarthritis, providing joint pain relief and improved mobility for knee, hip, ankle, shoulder, and other joints. Available in multiple molecular weight variants (Arsyvisc 1.6, 2.2) and mono-injection formulations (Arsyvisc Forté 2.5/3 ml, Arsyvisc Forté+ 2.5/4.8 ml). Indicated for osteoarthritis patients across multiple joints.
• HYAJOINT Plus Premium viscosupplementation solution with cross-linked hyaluronic acid ensuring prolonged efficacy and optimal protection of joints. Reduces knee pain associated with osteoarthritis and improves joint mobility, with effects lasting longer than linear hyaluronic acid formulations.
• ARSYPACK Complete sterile procedure kits for safe intra-articular injections. Fully sterile, adapted to routine procedures, containing all necessary components for infiltration in optimal hygiene and safety conditions. Designed for physicians, rheumatologists, and orthopaedic surgeons performing intra-articular injections.
• INNORYOS First 'visco-booster' combining hyaluronic acid and niacinamide for intra-articular injection, providing comprehensive joint protection. Targets finger and foot joints. Functions include lubrication, stabilization, and protection of joints. Marketed as the first visco-booster on the market.

Quantifiable outcome

• Viscosupplementation effects can last 6 to 12 months per treatment cycle
• +2 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Seven partnerships are on record, tiered core and minor.

• AEG Medical GroupcoreOthersARSYLAB is a subsidiary (société du Groupe) of AEG Medical Group. André-Alain Corbel, PDG of AEG Medical Group, joined the founders' adventure early on and brought strategic experience and support. Parent group provides corporate structure and strategic direction.
• GB PHARMAminorChannel Partner/ Reseller/ DistributorGB PHARMA serves as distributor for ARSYLAB products in French overseas territories: Guadeloupe, Martinique, and Guyana. Nathalie Demaret represents GB PHARMA as distributor contact.
• Olivier Surveillant (Commercial Agent)minorChannel Partner/ Reseller/ DistributorOlivier Surveillant serves as commercial agent for ARSYLAB in La Réunion (French overseas department). Provides local sales coverage and customer relationships in the territory.
• Dr Alexandre Martini (MPR Specialist)minorStrategic or Co-development PartnerDr Alexandre Martini, specialist in Physical Medicine and Rehabilitation, collaborated with ARSYLAB on a Wetlab focused on infiltration techniques and injection data. Represents professional medical collaboration for clinical training and product application guidance.
• Nicolas Fisselier (Physiotherapist-Osteopath)minorStrategic or Co-development PartnerNicolas Fisselier, Physiotherapist-Osteopath based in Rennes, collaborated with ARSYLAB to develop and present educational exercise videos for osteoarthritis patients (home exercise series). Long-term content partnership for patient education.
• Dr Lucas (Sports Medicine Physician)minorStrategic or Co-development PartnerDr Lucas, sports medicine physician in Saint-Brieuc, collaborated with ARSYLAB on educational content about running and knee osteoarthritis (gonarthrose), providing clinical expertise for the 'Journée Mondiale de la Course à Pied' content.
• Agence By MminorImplementation/ SI/ Consulting PartnerWebsite design agency for arsylab.com. Located at 91 route Nationale, 35650 Le Rheu. Responsible for site design and development.

Scale indicators3 records

Recent moves10 records

Expansion highlights5 records

Broad incumbents

• LG Chem (Life Sciences division): Diversified chemical/pharma group with HA viscosupplement (Hyruan/Supartz-style) lines. Overlapping product category with the scale and capital backing of a large conglomerate — analogous to ARSYLAB's positioning within AEG Medical Group.
• Ferring Pharmaceuticals: Established pharma group with EUFLEXXA, a leading HA viscosupplement for knee OA. Comparable in offering and prescriber audience, with the scale advantages of a multi-therapy specialty pharma company.
• Viatris (Mylan heritage — hyaluronate franchise): Global generics and specialty player distributing HA viscosupplements through European pharmacy networks. Comparable distribution model (pharmacy-led) and pricing pressure environment for non-reimbursed or partially reimbursed HA products.
• Sanofi (viscosupplement franchise — Synvisc/Synvisc-One): Global pharmaceutical incumbent with the Synvisc/Synvisc-One HA viscosupplementation franchise, the largest legacy brand in the category. Directly comparable product offering but with vastly broader portfolio, larger sales force, and typically reimbursed status in multiple European markets.

Direct peers

• Anika Therapeutics: Pure-play orthobiologics / viscosupplementation company (Monovisc, Orthovisc). Direct product overlap with ARSYLAB's single-injection HA offerings and the same physician/pharmacy channel dynamics.
• Fidia Farmaceutici: Italian specialty pharma company with a strong HA portfolio (Hyalgan, Hymovis) and deep European footprint. Closely comparable product range, regulatory approach, and HCP engagement model.
• TRB Chemedica: Specialty pharma with a dedicated viscosupplementation and ophthalmic viscoelastic portfolio (e.g., Ostenil). Directly competing in single-injection HA for osteoarthritis with similar specialty positioning.
• Bioventus: Orthobiologics specialist marketing Durolane and Gelsyn-3 (HA viscosupplements) across Europe. Closest direct competitor with overlapping product range (single-injection HA), the same category of HCP customers (orthopedists, rheumatologists), and a similar focus on joint preservation.
• IBSA Pharma: Swiss specialty pharma with a hyaluronic acid portfolio spanning intra-articular and dermo-cosmetic indications. Closely comparable in product modality, European-manufactured quality positioning, and HCP-driven commercial model.

Emerging players

• Seikagaku Corporation: Japanese HA specialist marketing viscosupplements (e.g., Adant, Gel-200) into European and Asian markets. Comparable product category with an emerging/regional posture outside its home market.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• YouTubeyoutube.com/channel/UCmPiOqwwFJIyIt7MAiR3ejw
• Facebookfacebook.com/arsycap
• LinkedInlinkedin.com/company/arsylab

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Arsycap